{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-006843","form_type":"8-K","ticker":null,"cik":"0000811240","company_name":"BIOLASE, INC","filed_at":"2023-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.149854+00:00","generated_at":"2026-06-20T16:17:47.426196+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BIOLASE receives Nasdaq bid price deficiency notice; 180 days to cure","bullets":["Common stock closed below $1.00 per share for 30 consecutive business days through Jan 10, 2023.","Company has 180 calendar days, until July 10, 2023, to regain compliance under Nasdaq Listing Rule 5550(a)(2).","To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days before Compliance Date.","If not cured, may seek additional 180-day period by providing intent to cure, potentially via reverse stock split.","Company intends to monitor closing bid price and consider available options to regain compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-006843","json":"https://secwatch.observer/filing/0001193125-23-006843.json","markdown":"https://secwatch.observer/filing/0001193125-23-006843.md","text":"https://secwatch.observer/filing/0001193125-23-006843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811240/000119312523006843/0001193125-23-006843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811240/000119312523006843/d405891d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:17:47.426196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c9519c67cf4f4852d351031794ffbb780da2ed1","claim":"BIOLASE, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"January 11, 2023, BIOLASE, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, ending on January 10, 2023, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or u","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/811240/000119312523006843/0001193125-23-006843-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}